Evolent Health, Inc (NYSE:EVH) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Evolent Health has a consensus analyst rating of “Moderate Buy” from 17 research firms, with 13 buy ratings, three holds, and one sell. The average 12-month price target is about $6.12.
• The company’s latest quarter showed better-than-expected EPS of -$0.02 versus the expected -$0.05, but revenue of $496.25 million missed estimates. Management also raised full-year 2026 revenue guidance to $2.4 billion to $2.6 billion.
• Recent analyst actions were mixed but mostly constructive, including price target cuts from BTIG and Truist alongside a Needham target increase to $5.00 and reaffirmed buy rating. Institutional investors also made notable moves, with Goldman Sachs sharply increasing its stake in the company.

Evolent Health, Inc (NYSE:EVH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seventeen research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $6.1154.

Several research analysts recently issued reports on EVH shares. BTIG Research dropped their price target on shares of Evolent Health from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. Truist Financial reduced their target price on shares of Evolent Health from $10.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, February 25th. BMO Capital Markets restated an "outperform" rating and issued a $3.50 target price on shares of Evolent Health in a research note on Wednesday, February 25th. Wall Street Zen upgraded shares of Evolent Health from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Evolent Health in a research note on Monday, March 2nd.

Institutional Trading of Evolent Health

Several large investors have recently added to or reduced their stakes in EVH. Brighton Jones LLC bought a new stake in Evolent Health during the fourth quarter worth about $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Evolent Health by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock worth $1,217,000 after buying an additional 3,572 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Evolent Health by 162.2% during the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock worth $26,861,000 after buying an additional 1,754,520 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Evolent Health during the first quarter worth approximately $252,000. Finally, Strs Ohio acquired a new position in shares of Evolent Health during the first quarter worth approximately $47,000.

Evolent Health Stock Performance

NYSE:EVH opened at $4.19 on Friday. Evolent Health has a 12-month low of $2.10 and a 12-month high of $12.06. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 2.34. The firm has a market capitalization of $468.22 million, a PE ratio of -0.88 and a beta of 0.83. The firm has a 50-day moving average price of $2.93 and a 200 day moving average price of $3.80.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. Evolent Health had a negative net margin of 26.29% and a positive return on equity of 0.32%. The firm had revenue of $496.25 million during the quarter, compared to analyst estimates of $534.00 million. During the same quarter in the prior year, the business posted $0.06 earnings per share. The company's quarterly revenue was up 2.6% compared to the same quarter last year. Research analysts anticipate that Evolent Health will post -0.23 earnings per share for the current fiscal year.

Evolent Health News Roundup

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent’s Q1 EPS loss of $0.02 was better than the expected loss of $0.05, suggesting profitability trends were slightly better than analysts feared. Evolent Health Q1 2026 Earnings Call Transcript
• Positive Sentiment: Needham raised its price target on EVH from $4.00 to $5.00 and reiterated a buy rating, pointing to additional upside from current levels. Needham Price Target Raise
• Positive Sentiment: The company also lifted full-year 2026 revenue guidance to a range of $2.4 billion to $2.6 billion, which signals management expects stronger business performance ahead. Evolent Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue of $496.25 million missed Wall Street’s $534.0 million estimate, so investors are weighing the top-line shortfall against better-than-expected earnings and upbeat guidance. Evolent Health Misses Q1 Revenue Estimates

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company's core offerings include care management solutions, population health analytics and clinical advisory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.